盈利预测、估值与评级：我们维持公司25-27年归母净利润预测为1.39/1.70/1.96亿元，对应EPS 分别为 0.19/0.23/0.26 元，公司医疗服务和医疗器械板块持续稳健发展，维持"买入"评级。 风险提示：伽马刀销售不及预期；被并购公司业绩不及预期；商誉减值风险；医院业务增长不及预期等 医疗器械板块国内高端升级，海外市场收入增速靓丽：2025 年上半年，医疗器械板块实现收入1.90 亿 元，同比增长2.80%，其中设备及耗材业务收入同比增长13.34%。国内市场公司通过产品和渠道的高端 升级实现高质量发展，市场份额稳中有进；海外市场成为重要增长引擎，2025 年上半年新增9 家渠道 商，驱动医疗器械海外收入同比增长35%。 收购长沙珂信肿瘤医院有限公司51%股权，医疗服务板块再下一城：长沙珂信是一家位于长沙的集医 疗、科研，预防、康复于一体的三级肿瘤专科医院，其被收购后有望和公司现有的四川友谊医院、苏州 广慈医院、重庆友方医院高效协同，和公司现有产业布局高度融合，有望进一步深化公司发展战略，公 司肿瘤特色有望进一步增强，医疗服务板块业绩有望持续增长，我们预计25H2 公司医疗服务板块利润 有望进 ...

Group 1 - The core announcement is that Meizhong Jiahe plans to raise approximately HKD 270 million through the placement of 48,723,600 new H shares, with a net amount of about HKD 260 million after expenses [1] - The placement price is set at HKD 5.54 per share, representing a discount of approximately 16.9% to the closing price of HKD 6.67 on July 21, 2025, and a discount of about 19.9% to the average closing price of HKD 6.92 over the previous five trading days [1] - The newly issued shares will account for approximately 6.6% of the existing issued share capital and about 6.2% of the enlarged share capital after the placement [1] Group 2 - The funds raised will be allocated for the construction of Shanghai Taihe Cheng Cancer Hospital, support for medical AI business needs, repayment of financial institution loans, and to supplement working capital [1] - The issuance is conducted under a general mandate granted by the shareholders' meeting and is expected to be completed on the second business day after obtaining listing approval, no later than July 29, 2025 [1]

Group 1 - The core point of the article is that Yingkang Life plans to acquire a 51% stake in Changsha Kexin Oncology Hospital for 357 million yuan, which will allow it to gain control and consolidate the hospital's financials [2] - Changsha Kexin, established in 2015, is a tertiary oncology specialty hospital with 420 beds and reported revenue of 273 million yuan and net profit of 33.43 million yuan for the first three quarters of 2024 [2] - The hospital has committed to achieving net profits of no less than 57 million yuan, 58 million yuan, and 60 million yuan for the years 2025 to 2027, totaling 175 million yuan, which represents a significant increase of 73%-82% compared to historical performance [2] Group 2 - The acquisition is part of Yingkang Life's "1+n" strategy, which aims to establish a regional center hospital that supports multiple satellite hospitals [2] - Currently, Yingkang Life operates three owned hospitals and seven managed institutions, with projected medical service revenue of 1.192 billion yuan in 2024, where oncology revenue is expected to account for 31.9% [3] - Following the acquisition, Yingkang Life's total assets are reported at 3.537 billion yuan, with a debt ratio of 29.93%, indicating that total liabilities may increase post-acquisition [3]